

Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/N596A36D5CEBEN.html>

Date: June 2020

Pages: 104

Price: US\$ 3,500.00 (Single User License)

ID: N596A36D5CEBEN

Abstracts

Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H1 2020

SUMMARY

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation.

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 25 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 3, 12 and 2 respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Dermatology, Central Nervous System, Infectious Disease, Respiratory and Undisclosed which include indications Psoriasis, Ulcerative Colitis, Inflammatory Bowel Disease, Crohn's Disease (Regional Enteritis), Systemic Lupus Erythematosus, Coronavirus Disease 2019 (COVID-19), Multiple Sclerosis, Rheumatoid Arthritis, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Hidradenitis Suppurativa, Inflammation, Plaque Psoriasis (Psoriasis Vulgaris), Psoriatic Arthritis, Vitiligo, Acute Lung Injury, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Fibrosis, Follicular

Lymphoma, Hypersensitivity, Kidney Cancer (Renal Cell Cancer), Lung Transplant Rejection, Lupus Erythematosus, Lupus Nephritis, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Skin Cancer, Unspecified and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

The latest report Non Receptor Tyrosine Protein Kinase TYK2 – Pipeline Review, H1 2020, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics
Development

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics
Development

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics
Assessment

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies
Involved in Therapeutics Development

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued
Products

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product
Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AbbVie Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Bristol-Myers Squibb Co, H1 2020
Pipeline by Galapagos NV, H1 2020
Pipeline by InnoCare Pharma Ltd, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Nimbus Therapeutics LLC, H1 2020
Pipeline by Oncostellae SL, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Portola Pharmaceuticals Inc, H1 2020
Pipeline by Sareum Holdings Plc, H1 2020
Pipeline by Simcere Pharmaceutical Group, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Pipeline by Theravance Biopharma Inc, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

AbbVie Inc

Amgen Inc

Bristol-Myers Squibb Co

Galapagos NV

InnoCare Pharma Ltd

Merck & Co Inc

Nimbus Therapeutics LLC

Oncostellae SL

Pfizer Inc

Portola Pharmaceuticals Inc

Sareum Holdings Plc

Simcere Pharmaceutical Group

Takeda Pharmaceutical Co Ltd

Theravance Biopharma Inc

I would like to order

Product name: Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/N596A36D5CEBEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N596A36D5CEBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970